who have both Nonalcoholic fatty liver disease (NAFLD) Diabetic patients were nearly 75% more likely than nondiabetic patients to develop at least one stage of fibrosis, according to findings published in . AASLD Liver Conference.
NAFLD, which results from the accumulation of fat in the liver, and its more serious form, non-alcoholic steatohepatitis (NASH), are responsible for the increasing rates of progressive liver disease worldwide. Fat accumulation in the liver is often associated with obesity and diabetes.As a result of inflammation, NAFLD is characterized by the accumulation of scar tissue (fibrosis), cirrhosis, and even liver cancerWith no approved effective treatments, management of the disease relies on lifestyle changes such as weight loss and exercise.
Diabetes is also associated with an increased incidence of severe fibrosis, cirrhosis and liver cancer. Daniel Huang (MBBS) of the University of California, San Diego and his colleagues investigated the extent to which fibrosis progressed in patients with biopsy-confirmed NAFLD, with and without diabetes.
In this study, researchers included adults with NAFLD who had liver biopsies paired at least one year apart. We were recruited.
At baseline, 208 participants had diabetes and 239 did not. Participants who had diabetes at baseline were more likely to be older and female. They also had a higher body mass index and a higher baseline fibrosis stage.
Of the 447 participants, 35% experienced fibrosis progression, 23% experienced fibrosis regression, and 43% experienced no change. The researchers found that diabetics had a higher rate of fibrosis progression than nondiabetics, with more diabetics progressing to advanced fibrosis (26% vs. 14%). Diabetes was an independent risk factor for fibrosis progression even after adjusting for other factors.
People with diabetes had a 73% higher risk of developing at least one stage of fibrosis (such as mild to moderate or moderate to severe) than nondiabetics. Among diabetics, fibrosis progresses by 0.17 steps per year. In other words, it will take 5.9 years to progress one stage. In non-diabetics, fibrosis progresses by 0.13 steps per year. This means it will take him 7.7 years to progress one step. On the other hand, the rate of fibrosis regression was similar in people with and without diabetes, with fibrosis regressing by one step in 7.7 vs. 7.1 years, respectively.
“Using paired liver biopsy data from a unique, well-represented, multicenter prospective cohort study, diabetic patients with NAFLD had a significantly higher
rate of progression of fibrosis,” the researchers concluded. “These data have important implications for clinical practice and the design of clinical trials.” They said that people with NAFLD and diabetes may need to be monitored more frequently for liver disease progression. suggested.
Click here for more reports from liver meeting.
Click here for more news about fatty liver disease.